Osimertinib (TAGRISSO), a once-daily tablet indicated for the treatment of specific lung cancers, has been granted accelerated approval by the U.S. Food and Drug Administration (FDA).
Osimertinib, a product of AstraZeneca Pharmaceuticals LP, can be used to treat patients who have had a positive, FDA-approved test for metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
Additionally, patients must have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy in order to qualify for the treatment.
